<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-21T15:48:57Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/277271" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/277271</identifier><datestamp>2021-04-21T18:05:34Z</datestamp><setSpec>com_1810_263984</setSpec><setSpec>com_1810_221767</setSpec><setSpec>com_1810_256067</setSpec><setSpec>col_1810_263986</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>MECHANISM OF PINK1-MEDIATED UBIQUITIN PHOSPHORYLATION</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.24555</dc:identifier>
   <dc:creator>Schubert, Alexander Fabian</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000218343787</uketdterms:authoridentifier>
   <uketdterms:advisor>Komander, David</uketdterms:advisor>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000280924320</uketdterms:authoridentifier>
   <dcterms:abstract>Ubiquitin phosphorylation by PINK1 (PTEN-induced Putative Kinase 1) is crucial for
mitochondrial quality control and loss or mutation of PINK1 can lead to autosomal
recessive juvenile parkinsonism (AR-JP).
PINK1 is an unusual kinase, as it is characterised by three unique insertions in its
kinase N lobe and a C-terminal region after the kinase domain. Despite great effort, a
structure of PINK1 could not be determined and the molecular mechanism of
ubiquitin phosphorylation and the effect of the PINK1 AR-JP patient mutations
remained elusive. The versatile modifier ubiquitin (Ub) is also an unusual kinase
substrate, as its phosphorylation site (Ser65) is not exposed, but protected by the Ub
fold. Hence, it was not clear how a kinase would be able to target Ser65 of Ub.
This work shows that Ub needs to adopt a previously described conformation in order
to be efficiently phosphorylated by PINK1. NMR experiments revealed that in a small
population of Ub the last β-strand is retracted, resulting in a more accessible Ser65
loop. It could be shown that PINK1 binds the Ser65 loop in this C-terminally retracted
conformation (Ub-CR), but not in the ‘common’ conformation. In addition, it could
be shown that Ub trapped in the Ub-CR conformation by point mutations (Ub TVLN)
is phosphorylated significantly faster than Ub wt, which only adopts the Ub-CR
conformation at very low frequency.
To further elucidate how PINK1 binds and phosphorylates Ub, the kinase domain of
Pediculus humanus corporis (Ph)PINK1 was crystallised in complex with Ub TVLN
stabilised by a nanobody. The structure revealed many peculiarities of PINK1, such as
the architecture of the unique insertions and the C-terminal region. Together with
NMR and mass spectrometry studies, the structure explains how PINK1 interacts with
ubiquitin via insertion-3 and its activation segment, and how PINK1 utilises the Ub-
CR conformation for efficient Ser65 phosphorylation. In addition, the structure shows
that two autophosphorylation sites in the N lobe regulate PINK1, by stabilising the
functionally important insertions. The structure helped our understanding of the
molecular basis of over 40 AR-JP patient mutations and may guide the design of ARJP
therapeutics in the future.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2018-07-20</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>en</dc:language>
   <uketdterms:sponsor>MRC Research Studentship program</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/277271</dcterms:isReferencedBy>
   <dcterms:license>https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/309777c8-1df1-46d8-9ace-21813d7970c3/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/b9272310-480c-4ef7-840b-1741fa48454c/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">4e2616df1f5ffdcae289a48a62b83141</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>PINK1</dc:subject>
   <dc:subject>Kinase</dc:subject>
   <dc:subject>Parkinson's disease</dc:subject>
   <dc:subject>Structural biology</dc:subject>
   <dc:subject>Ubiquitin</dc:subject>
   <dc:subject>Mitophagy</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>